{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:30:07Z","timestamp":1793989807319,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000919","name":"Open Society Foundations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000919","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mainline"},{"DOI":"10.13039\/100004417","name":"Global Fund to Fight AIDS, Tuberculosis and Malaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016961","name":"National Institute for the Humanities and Social Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016961","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Moral conservatism within government and communities has resulted in a reluctance to support the provision of opioid agonist therapy for people with opioid use disorders in South Africa. In April 2017, South Africa\u2019s first low-threshold opioid agonist therapy demonstration project was launched in Durban. The project provided 54 low-income people with heroin use disorders methadone and voluntary access to psychosocial services for 18\u2009months. At 12 months, retention was 74%, notably higher than the global average. In this paper, we aim to make sense of this outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty semi-structured interviews, two focus groups, ten oral histories and ethnographic observations were done at various project time points. These activities explored participants\u2019 pathways into drug use and the project, their meaning attributed to methadone, the factors contributing to project success and changes they experienced. Recordings, transcripts, notes and feedback were reviewed and triangulated. Key factors contributing to retention were identified and analysed in light of the existing literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The philosophy and architecture of the project, and social cohesion were identified as the main factors contributing to retention. The use of a harm reduction approach enabled participants to set and be supported to achieve their treatment goals, and was shown to be important for the development of trusting therapeutic relationships. The employment of a restorative justice paradigm provided a sense of acceptance of humanity and flaws as well as an imperative to act responsibly towards others, fostering a culture of respect. Social cohesion was fostered through the facilitation of group sessions, a peace committee and group sport (soccer). In concert, these activities provided opportunities for participants to demonstrate care and interest in one another\u2019s life, leading to interdependence and care, contributing to them remaining in the project.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We believe that the high retention was achieved through attraction. We argue that opioid agonist therapy programmes should take the principles of harm reduction and restorative justice into consideration when designing low-threshold opioid agonist therapy services. Additionally, ways to support cohesion amongst people receiving agonist therapy should be explored to support their effective scale-up, both in low-middle income countries and in high-income countries.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-020-00368-1","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T16:03:52Z","timestamp":1586966632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion"],"prefix":"10.1186","volume":"17","author":[{"given":"Monique","family":"Marks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Scheibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Shelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"368_CR1","volume-title":"Hiding in plain sight. Heroin\u2019 s stealthy takeover of South Africa. Policy Brief","author":"S Haysom","year":"2019","unstructured":"Haysom S. Hiding in plain sight. Heroin\u2019 s stealthy takeover of South Africa. Policy Brief. Pretoria: ENACT; 2019."},{"key":"368_CR2","first-page":"1","volume":"14","author":"A Khine","year":"2015","unstructured":"Khine A, Mokwena K, Huma, Mempedi, Fernandes L. Identifying the composition of street drug Nyaope using two different mass spectrometer methods. African J Drug Alcohol Stud. 2015;14:1.","journal-title":"African J Drug Alcohol Stud"},{"issue":"2","key":"368_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/1741659015588402","volume":"11","author":"S Howell","year":"2015","unstructured":"Howell S. \u2018We have to start showing who is boss now\u2019: constructing methamphetamine use and users in the South African print media. Crime Media Cult. 2015;11(2):137\u201356.","journal-title":"Crime Media Cult"},{"issue":"2","key":"368_CR4","first-page":"318","volume":"31","author":"M Marks","year":"2016","unstructured":"Marks M, Howell S, Shelly S. The fluidity of \u2018police culture\u2019: encountering the contextual complexity of policing street-level drug use. Policing. 2016;31(2):318\u201331.","journal-title":"Policing."},{"key":"368_CR5","unstructured":"Dada S, Harker N, Jodilee B, Warren E, Parry C, Bhana A, et al. April 2019 | phase 44. SA Medical Research Council; 2019."},{"issue":"10","key":"368_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.7196\/SAMJ.2018.v108i10.13397","volume":"108","author":"A Scheibe","year":"2018","unstructured":"Scheibe A, Marks M, Shelly S, Gerardy T, Domingo A, Hugo J. Developing an advocacy agenda for increasing access to opioid substitution therapy as part of comprehensive services for people who use drugs in South Africa. S Afr Med J. 2018;108(10):800\u20132.","journal-title":"S Afr Med J"},{"key":"368_CR7","doi-asserted-by":"crossref","unstructured":"Connery HS. Medication-assisted treatment of opioid use and future directions. Harv Rev Psychiatry. 2015:63\u201375.","DOI":"10.1097\/HRP.0000000000000075"},{"key":"368_CR8","doi-asserted-by":"crossref","unstructured":"Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;10.","DOI":"10.1002\/14651858.CD004147.pub4"},{"issue":"2","key":"368_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/bcp.12031","volume":"77","author":"MP Garcia-Portilla","year":"2014","unstructured":"Garcia-Portilla MP, Bobes-Bascaran MT, Bascaran MT, Saiz PA, Bobes J. Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack? Br J Clin Pharmacol. 2014;77(2):272\u201384 Available from: https:\/\/bpspubs-onlinelibrary-wiley-com.uplib.idm.oclc.org\/doi\/epdf\/10.1111\/bcp.12031.","journal-title":"Br J Clin Pharmacol"},{"key":"368_CR10","volume-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"WHO","year":"2009","unstructured":"WHO. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO; 2009."},{"issue":"2","key":"368_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","volume":"30","author":"JC Veilleux","year":"2010","unstructured":"Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155\u201366.","journal-title":"Clin Psychol Rev."},{"issue":"6","key":"368_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1360-0443.2008.02188.x","volume":"103","author":"DM Novick","year":"2008","unstructured":"Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction. 2008;103(6):905\u201318.","journal-title":"Addiction."},{"issue":"9","key":"368_CR13","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","volume":"103","author":"P Lawrinson","year":"2008","unstructured":"Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS. Addiction. 2008;103(9):1484\u201392.","journal-title":"Addiction."},{"issue":"14","key":"368_CR14","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2174\/138161211796150855","volume":"17","author":"A Benyamina","year":"2011","unstructured":"Benyamina A, Reynaud M, Blecha L, Karila L. Pharmacological treatments of opiate dependence. Curr Pharm Des. 2011;17(14):1384\u20138.","journal-title":"Curr Pharm Des."},{"issue":"6","key":"368_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/01.yco.0000245759.13997.9d","volume":"19","author":"C Haasen","year":"2006","unstructured":"Haasen C, van den Brink W. Innovations in agonist maintenance treatment of opioid-dependent patients. Curr Opin Psychiatry. 2006;19(6):631\u20136.","journal-title":"Curr Opin Psychiatry."},{"issue":"2","key":"368_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1176\/appi.ps.201300235","volume":"65","author":"CA Fullerton","year":"2014","unstructured":"Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146\u201357.","journal-title":"Psychiatr Serv."},{"issue":"1","key":"368_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/add.12303","volume":"109","author":"J Feelemyer","year":"2014","unstructured":"Feelemyer J, Des Jarlais D, Arasteh K, Abdul-Quader AS, Hagan H. Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. Addiction. 2014 Jan;109(1):20\u201332.","journal-title":"Addiction."},{"key":"368_CR18","doi-asserted-by":"crossref","unstructured":"Obot IS. Commentary on Freelemyer et\u2009al . Medication-assisted treatment in Africa-need is growing but response remains tepid. Addiction. 2014;109(1):33\u201334.","DOI":"10.1111\/add.12364"},{"issue":"5","key":"368_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.drugpo.2008.10.005","volume":"20","author":"H Keane","year":"2009","unstructured":"Keane H. Foucault on methadone: beyond biopower. Int J Drug Policy. 2009;20(5):450\u20132.","journal-title":"Int J Drug Policy."},{"issue":"6","key":"368_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/1049732311432718","volume":"22","author":"J Harris","year":"2012","unstructured":"Harris J, McElrath K. Methadone as social control. Qual Health Res. 2012;22(6):810\u201324.","journal-title":"Qual Health Res."},{"issue":"8","key":"368_CR21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","volume":"104","author":"L Burns","year":"2009","unstructured":"Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, et al. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction. 2009;104(8):1363\u201372.","journal-title":"Addiction."},{"issue":"1","key":"368_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.drugalcdep.2013.10.011","volume":"134","author":"JP Feelemyer","year":"2014","unstructured":"Feelemyer JP, Des Jarlais DC, Arasteh K, Phillips BW, Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 2014;134(1):251\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"368_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/09595239500185371","volume":"14","author":"E Single","year":"1995","unstructured":"Single E. Defining harm reduction. Drug Alcohol Rev. 1995;14(3):287\u201390.","journal-title":"Drug Alcohol Rev."},{"issue":"August","key":"368_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsat.2018.08.009","volume":"94","author":"A Lo","year":"2018","unstructured":"Lo A, Kerr T, Hayashi K, Milloy MJ, Nosova E, Liu Y, et al. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. J Subst Abuse Treat. 2018;94(August):41\u20136 Available from: https:\/\/doi.org\/10.1016\/j.jsat.2018.08.009.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"368_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jsat.2009.09.002","volume":"38","author":"C Lin","year":"2010","unstructured":"Lin C, Wu Z, Rou K, Yin W, Wang C, Shoptaw S, et al. Structural-level factors affecting implementation of the methadone maintenance therapy program in China. J Subst Abuse Treat. 2010;38(2):119\u201327.","journal-title":"J Subst Abuse Treat."},{"key":"368_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/753409","volume":"13","author":"TKS Christie","year":"2013","unstructured":"Christie TKS, Murugesan A, Manzer D, Shaughnessey MVO, Webster D. Evaluation of a low-threshold \/ high-tolerance methadone maintenance treatment clinic in Saint John, New Brunswick, Canada: One Year Retention Rate and Illicit Drug Use. J Addict. 2013;13:1\u20135 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4008509\/pdf\/JADD2013-753409.pdf.","journal-title":"J Addict"},{"key":"368_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","volume":"161","author":"G Kourounis","year":"2016","unstructured":"Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori M-M, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1\u20138 Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871615018360.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"368_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0376-8716(96)01230-6","volume":"41","author":"M Torrens","year":"1996","unstructured":"Torrens M, Castillo C, P\u00e9rez-Sol\u00e1 V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 1996;41(1):55\u20139 Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0376871696012306.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"368_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bcp.12051","volume":"77","author":"J Bell","year":"2014","unstructured":"Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77(2):253\u201363.","journal-title":"Br J Clin Pharmacol."},{"key":"368_CR30","first-page":"1","volume":"43","author":"Center for Substance Abuse Treatment, SAMHSA, Center for Substance Abuse Treatment, SAMHSA","year":"2012","unstructured":"Center for Substance Abuse Treatment, SAMHSA, Center for Substance Abuse Treatment, SAMHSA. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treat Improv Protoc. 2012;43:1\u2013358.","journal-title":"Treat Improv Protoc"},{"key":"368_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jsat.2011.07.009","volume":"42","author":"R Sarasvita","year":"2012","unstructured":"Sarasvita R, Tonkin A, Utomo B, Ali R. Predictive factors for treatment retention in methadone programs in Indonesia. J Subst Abuse Treat. 2012;42:239\u201346.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"368_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.drugpo.2009.10.005","volume":"21","author":"M Schaub","year":"2010","unstructured":"Schaub M, Chtenguelov V, Subata E, Weiler G, Uchtenhagen A. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine. Int J Drug Policy. 2010;21(3):229\u201333.","journal-title":"Int J Drug Policy."},{"issue":"1","key":"368_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000320576","volume":"17","author":"H St\u00f6ver","year":"2010","unstructured":"St\u00f6ver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2010;17(1):44\u201354.","journal-title":"Eur Addict Res."},{"issue":"10","key":"368_CR34","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/070674370605101003","volume":"51","author":"WW Van Den Brink","year":"2006","unstructured":"Van Den Brink WW, Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry-Revue Can Psychiatr. 2006;51(10):635\u201346.","journal-title":"Can J Psychiatry-Revue Can Psychiatr."},{"issue":"1","key":"368_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22\u201335 Available from: http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10550887.2016.1100960.","journal-title":"J Addict Dis"},{"issue":"1","key":"368_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12954-016-0124-z","volume":"13","author":"E Ruadze","year":"2016","unstructured":"Ruadze E, Todadze K. Retention in Georgia opioid substitution therapy program and associated factors. Harm Reduct J. 2016;13(1):35.","journal-title":"Harm Reduct J."},{"issue":"3","key":"368_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/add.12693","volume":"110","author":"WR Miller","year":"2015","unstructured":"Miller WR, Moyers TB. The forest and the trees: relational and specific factors in addiction treatment. Addiction. 2015;110(3):401\u201313.","journal-title":"Addiction."},{"issue":"1","key":"368_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drugalcdep.2005.10.010","volume":"83","author":"PSPS Meier","year":"2006","unstructured":"Meier PSPS, Donmall MC, McElduff P, Barrowclough C, Heller RFRF, Ackerman SJ, et al. The role of the early therapeutic alliance in predicting drug treatment dropout. Drug Alcohol Depend. 2006;83(1):57\u201364.","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"368_CR39","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1360-0443.2004.00935.x","volume":"100","author":"PS Meier","year":"2005","unstructured":"Meier PS, Barrowclough C, Donmall MC, Meier P. The role of the therapeutic alliance in the treatment of substance misuse\u00a0: a critical review of the literature. Addiction. 2005;100(3):304\u201316.","journal-title":"Addiction."},{"issue":"1","key":"368_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-016-0086-x","volume":"12","author":"K Zhou","year":"2017","unstructured":"Zhou K, Li H, Wei X, Yin J, Liang P, Zhang H, et al. Relationships between received and perceived social support and health-related quality of life among patients receiving methadone maintenance treatment in Mainland China. Subst Abus Treat Prev Policy. 2017;12(1):1\u20138.","journal-title":"Subst Abus Treat Prev Policy."},{"issue":"6","key":"368_CR41","first-page":"1","volume":"12","author":"K Zhou","year":"2017","unstructured":"Zhou K, Wang D, Li H, Wei X, Yin J, Liang P, et al. Bidirectional relationships between retention and health-related quality of life in Chinese mainland patients receiving methadone maintenance treatment. PLoS One. 2017;12(6):1\u201312.","journal-title":"PLoS One."},{"issue":"3","key":"368_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.drugpo.2008.02.009","volume":"19","author":"BB Pauly","year":"2008","unstructured":"Pauly BB. Shifting moral values to enhance access to health care: harm reduction as a context for ethical nursing practice. Int J Drug Policy. 2008;19(3):195\u2013204.","journal-title":"Int J Drug Policy."},{"issue":"11","key":"368_CR43","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3109\/10826089809056260","volume":"33","author":"P Bourgois","year":"1998","unstructured":"Bourgois P. The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments. Subst Use Misuse. 1998;33(11):2323\u201351.","journal-title":"Subst Use Misuse."},{"issue":"11","key":"368_CR44","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1037\/0003-066X.43.11.865","volume":"43","author":"D Des Jarlais","year":"1988","unstructured":"Des Jarlais D, Friedman S. The psychology of preventing AIDS among intravenous drug users. Am Psychol. 1988;43(11):865\u201370.","journal-title":"Am Psychol."},{"issue":"8","key":"368_CR45","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1177\/0002764204274194","volume":"48","author":"E Rice","year":"2005","unstructured":"Rice E, Milburn NG, Rotheram-Borus MJ, Mallett S, Rosenthal D. The effects of peer group network properties on drug use among homeless youth. Am Behav Sci. 2005;48(8):1102\u201323.","journal-title":"Am Behav Sci."},{"issue":"3","key":"368_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drugpo.2012.12.005","volume":"24","author":"K Foster","year":"2013","unstructured":"Foster K, Spencer D. \u201cIt\u2019s just a social thing\u201d: drug use, friendship and borderwork among marginalized young people. Int J Drug Policy. 2013;24(3):223\u201330.","journal-title":"Int J Drug Policy."},{"issue":"2","key":"368_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ptr\/12.2.213","volume":"12","author":"JA Gillaspy","year":"2002","unstructured":"Gillaspy JA, Wright AR, Campbell C, Stokes S, Adinoff B. Group alliance and cohesion as predictors of drug and alcohol abuse treatment outcomes. Psychother Res. 2002;12(2):213\u201329.","journal-title":"Psychother Res."},{"key":"368_CR48","volume-title":"The theory and practice of group psychotherapy, 5th ed","author":"ID Yalom","year":"2005","unstructured":"Yalom ID. The theory and practice of group psychotherapy. In: Leszcz M, editor. The theory and practice of group psychotherapy, 5th ed. 5th ed. New York: Basic Books; 2005.","edition":"5"},{"issue":"5","key":"368_CR49","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0277-9536(01)00204-0","volume":"55","author":"AM Lovell","year":"2002","unstructured":"Lovell AM. Risking risk: the influence of types of capital and social networks on the injection practices of drug users. Soc Sci Med. 2002;55(5):803\u201321.","journal-title":"Soc Sci Med."},{"key":"368_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jsat.2016.10.004","volume":"73","author":"SE Zemore","year":"2017","unstructured":"Zemore SE, Kaskutas LA, Mericle A, Hemberg J. Comparison of 12-step groups to mutual help alternatives for AUD in a large, national study: differences in membership characteristics and group participation, cohesion, and satisfaction. J Subst Abuse Treat. 2017;73:16\u201326.","journal-title":"J Subst Abuse Treat."},{"issue":"4","key":"368_CR51","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/01609513.2014.905217","volume":"37","author":"DK Pooler","year":"2014","unstructured":"Pooler DK, Qualls N, Rogers R, Johnston D. An exploration of cohesion and recovery outcomes in addiction treatment groups. Soc Work Groups. 2014;37(4):314\u201330.","journal-title":"Soc Work Groups."},{"key":"368_CR52","first-page":"197","volume":"20","author":"A Scheibe","year":"2017","unstructured":"Scheibe A, Shelly S, Versfeld A, Howell S, Marks M. Safe treatment and treatment of safety: call for a harm-reduction approach to drug-use disorders in South Africa. South African Heal Rev. 2017;20:197\u2013204.","journal-title":"South African Heal Rev."},{"key":"368_CR53","volume-title":"The alcohol. Smoking and substance involvement screening test","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. The alcohol. Smoking and substance involvement screening test. Geneva: WHO; 2010."},{"key":"368_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-1-8","volume":"1","author":"T Ruefli","year":"2004","unstructured":"Ruefli T, Rogers SJ. How do drug users define their progress in harm reduction programs? Qualitative research to develop user-generated outcomes. Harm Reduct J. 2004;1:1\u201313.","journal-title":"Harm Reduct J."},{"key":"368_CR55","volume-title":"South African guidelines for the management of opioid dependence. Updated 2013","author":"L Weich","year":"2013","unstructured":"Weich L, Nowbath H, Flegar S, Mahomedy Z, Ramjee H, Hitzeroth V, et al. South African guidelines for the management of opioid dependence. Updated 2013. Pretoria: South African Addiction Medicine Society; 2013."},{"issue":"13","key":"368_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-020-00186-7","volume":"15","author":"A Scheibe","year":"2020","unstructured":"Scheibe A, Shelly S, Gerardy T, Von Homeyer Z, Schneider A, Padayachee K, et al. Six - month retention and changes in quality of life and substance use from a low - threshold methadone maintenance therapy programme in Durban, South Africa. Addict Sci Clin Pract. 2020;15(13):1\u201311 Available from: https:\/\/doi.org\/10.1186\/s13722-020-00186-7.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"368_CR57","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/bjc\/42.3.514","volume":"42","author":"D Roche","year":"2002","unstructured":"Roche D. Restorative justice and the regulatory state in South African townships. Br J Criminol. 2002;42(3):514\u201333.","journal-title":"Br J Criminol."},{"issue":"3","key":"368_CR58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/0309133308089372","volume":"32","author":"G Valentine","year":"2008","unstructured":"Valentine G. Living with difference: reflections on geographies of encounter. Prog Hum Geogr. 2008;32(3):323\u201337.","journal-title":"Prog Hum Geogr."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00368-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-020-00368-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00368-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:15:49Z","timestamp":1618445749000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00368-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1186\/s12954-020-00368-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"20 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Research Ethics Committee of the Durban University of Technology (reference: Invisible Lives: Pathways into and out of street-level drug use in Durban) and the KwaZulu-Natal Department of Health\u2019s Research Ethics Committee (reference KZ_2016RP14_267). Participants provided written informed consent and were not remunerated for participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Potential participants were given an information sheet about the study. On entering the project, all participants signed the consent form. Within the consent form is the granting of permission to disseminate the anonymised results in journals, at conferences and in a study report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}